PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Recently, the development of immunotherapy through the immune checkpoint blockade led to long-lasting responses in several types of cancers that are refractory to conventional treatments, such as melanoma or non-small cell lung cancer. Immunotherapy has also demonstrated significant improvements in...
Main Authors: | Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, Renaud Sabatier, Anthony Gonçalves |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/7/1033 |
Similar Items
-
Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
by: Huimei Yi, et al.
Published: (2021-05-01) -
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
by: Qingyang Lei, et al.
Published: (2020-07-01) -
PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer
by: Sandeep Kumar Parvathareddy, et al.
Published: (2021-01-01) -
Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
by: Zhiyang Li, et al.
Published: (2021-03-01) -
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
by: Mina LA, et al.
Published: (2020-01-01)